Want to see GB:CNSL full AI Analyst Report?
Omega Diagnostics (CNSL) AI Stock Analysis
Top Page
Omega Diagnostics
(LSE:CNSL)
The low overall score is driven mainly by poor financial performance from volatile revenues and negative cash flows, compounded by weak valuation metrics. Technical indicators offer limited positive momentum but are constrained by overbought signals.
Omega Diagnostics (CNSL) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- GBP 3.69M
- Dividend Yield
- ―
- Average Volume (3M)
- 441.38K
- Price to Earnings (P/E)
- -0.6
- Beta (1Y)
- 1.01
- Revenue Growth
- -16.27%
- EPS Growth
- -471.21%
- Country
- UK
- Employees
- 85
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Instruments & Supplies
Omega Diagnostics Business Overview & Revenue Model
Company Description
Established in 1987 and headquartered in London, UK, Cambridge Nutritional Sciences plc (formerly Omega Diagnostics Group PLC until its name change in September 2023) is a specialist in the development, manufacturing, and supply of medical diagnostic...
How the Company Makes Money
Omega Diagnostics makes money primarily by selling diagnostic products and related components into healthcare, laboratory, and industrial supply chains. Key revenue streams typically include: (1) sales of finished IVD test kits (e.g., rapid tests and...
Omega Diagnostics Financial Statement Overview
Summary
Weak income statement and cash flow scores due to revenue declines, net losses, and ongoing cash burn, partially offset by a moderate balance sheet with low debt.
Income Statement
28NegativeBalance Sheet
48NeutralCash Flow
22Negative| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.97M | 6.97M | 8.33M | 9.77M | 7.55M | 8.54M |
| Gross Profit | 4.28M | 4.28M | 5.00M | 6.05M | 3.17M | 4.75M |
| EBITDA | -391.00K | -392.00K | 2.20M | -73.00K | -2.65M | 360.00K |
| Net Income | -5.83M | -5.83M | 1.57M | -328.00K | -3.86M | -11.33M |
Balance Sheet | ||||||
| Total Assets | 7.45M | 7.45M | 13.80M | 13.89M | 14.40M | 17.84M |
| Cash, Cash Equivalents and Short-Term Investments | 2.64M | 2.64M | 4.87M | 5.44M | 5.12M | 1.60M |
| Total Debt | 125.00K | 125.00K | 349.00K | 148.00K | 74.00K | 370.00K |
| Total Liabilities | 1.77M | 1.77M | 2.39M | 4.21M | 4.45M | 6.02M |
| Stockholders Equity | 5.68M | 5.68M | 11.41M | 9.68M | 9.95M | 11.82M |
Cash Flow | ||||||
| Free Cash Flow | -1.39M | -1.39M | -142.00K | 548.00K | -3.31M | -4.71M |
| Operating Cash Flow | -1.13M | -1.13M | 83.00K | 607.00K | -3.15M | -3.23M |
| Investing Cash Flow | -810.00K | -810.00K | 2.12M | -2.51M | 5.18M | -493.00K |
| Financing Cash Flow | -232.00K | -232.00K | -251.00K | -265.00K | 1.49M | -502.00K |
Omega Diagnostics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:CNSL, the sentiment is Negative. The current price of 1.55 is below the 20-day moving average (MA) of 1.60, below the 50-day MA of 1.61, and below the 200-day MA of 1.83, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 41.14 is Neutral, neither overbought nor oversold. The STOCH value of 36.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:CNSL.
Omega Diagnostics Peers Comparison
Overall Rating
GB:TSTL80Outperform
GB:AMS67Neutral
GB:EKF64Neutral
GB:IXI64Neutral
GB:ABDX46Neutral- GB:CNSL41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| GB:TSTL | 80Outperform | GBP 194.70M | 24.28 | 23.05% | 3.51% | 10.02% | 19.83% |
| GB:AMS | 67Neutral | GBP 611.34M | 166.18 | 1.44% | 1.66% | 6.05% | -60.00% |
| GB:EKF | 64Neutral | GBP 102.71M | 41.38 | 3.58% | ― | 2.26% | -57.04% |
| GB:IXI | 64Neutral | GBP 25.73M | -5.99 | -16.18% | ― | 13.04% | 15.88% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| GB:ABDX | 46Neutral | GBP 22.75M | -16.36 | -34.31% | ― | 30.42% | 43.16% |
| GB:CNSL | 41Neutral | GBP 3.69M | -0.63 | -69.62% | ― | -16.27% | -471.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:CNSL | Omega Diagnostics | 1.55 | -1.10 | -41.51% | |
| GB:AMS | Advanced Medical Solutions | 282.50 | 67.49 | 31.39% | |
| GB:EKF | EKF Diagnostics Holdings | 24.00 | -2.20 | -8.40% | |
| GB:IXI | IXICO plc | 11.75 | 0.25 | 2.17% | |
| GB:TSTL | Tristel plc | 405.00 | 58.67 | 16.94% | |
| GB:ABDX | Abingdon Health PLC | 9.00 | 2.75 | 44.00% |
Omega Diagnostics Corporate Events
Cambridge Nutritional Sciences Reschedules AGM and Publishes 2026 Annual Report
NeutralCambridge Nutritional Sciences plc has rescheduled and finalised the notice of its Annual General Meeting for the financial year ended 31 March 2026. The AGM will now take place on 28 October 2026 at 2:00 p.m. at E-space North in Ely, ensuring compli...
Cambridge Nutritional Sciences Publishes Annual Report and Sets September AGM
NeutralCambridge Nutritional Sciences plc has published its Notice of Annual General Meeting and Annual Report and Accounts for the year ended 31 March 2026 on its corporate website. The documents provide shareholders and market participants with updated fi...
Cambridge Nutritional Sciences Cuts Costs and Refocuses Growth Amid Profit Slump
NegativeCambridge Nutritional Sciences reported a decline in annual revenues to £7.0 million and a swing to a pre-tax loss of £4.4 million, hurt by delayed customer spending and a £3 million goodwill impairment, even as gross margins improved...
Cambridge Nutritional Sciences Delays Full-Year Results, Confirms Guidance
NeutralCambridge Nutritional Sciences plc, a specialist medical diagnostics company listed on AIM, focuses on personalised and functional health and nutrition solutions. The group operates in the nutrition diagnostics segment, where demand is being driven b...
Cambridge Nutritional Sciences Sets Date for 2026 Results and Investor Presentation
PositiveCambridge Nutritional Sciences plc has scheduled the publication of its audited results for the year ended 31 March 2026 for Tuesday, 18 August 2026, signaling an upcoming update on the company’s financial and operational performance. Managemen...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 15, 2026